Articles From: Pulaski Financial Declares Quarterly Cash Dividend to Puradyn Releases 2014 2nd Quarter Unaudited Financial Results


2014/9/24
Pulaski Financial Corp.
Sign-up for Pulaski Financial Declares Quarterly Cash Dividend investment picks
2014/7/29
Pulaski Financial Corp.
Sign-up for Pulaski Financial Reports 47% Linked Quarter Increase in Third Fiscal Quarter Diluted EPS investment picks
Pulse Electronics Corporation (NYSE:PULS), a leading provider of electronic components, today announced that its Board of Directors has named Alan H.
Sign-up for Pulse Electronics Announces Chairman and CEO Transition investment picks
Pulse Electronics Corporation (“Pulse Electronics”) (NYSE: PULS), a leading provider of electronics components, announced today that it has submitted written notice to the New York Stock Exchange (the “NYSE”) of its decision to voluntarily delist its common stock from the NYSE and to deregister its common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). After careful consideration, Pulse Electronics’ board of directors decided to delist from the NYSE and deregister its common stock with the Securities and Exchange Commission (the "SEC") as it believes that the savings that will benefit the company and its shareholders outweigh the advantages of continuing as a NYSE listed and SEC reporting company.
Sign-up for Pulse Electronics Announces Initiative to Reduce Costs Through Voluntary NYSE Delisting and SEC Deregistration investment picks
Pulse Electronics Corporation (NYSE:PULS), a leading provider of electronic components, today reported results for its second quarter ended June 27, 2014.
Sign-up for Pulse Electronics Corporation Reports Second Quarter Results investment picks
Pulse Electronics Corporation (NYSE: PULS), a leading provider of electronic components, announced today it will report financial results for its second quarter on August 5, 2014, after the market closes.
Sign-up for Pulse Electronics Corporation Schedules Second Quarter Earnings Release and Conference Call investment picks
Pulse Electronics Corporation (NYSE: PULS), a leading provider of electronic components, has extended its inductor product offerings with a new line of high frequency multilayer ceramic chip inductors.
Sign-up for Pulse Electronics Extends Line with High Frequency Multilayer Ceramic Chip Inductors investment picks
Pulse Electronics Corporation (NYSE:PULS) has been in contact with the NYSE and has no comment regarding recent activity in its stock.
Sign-up for Pulse Electronics on Recent Stock Activity investment picks
Pulse Electronics Corporation (NYSE: PULS), a leading provider of electronic components, introduces its new 50Hz/60Hz, di/dt AC current sensor that can be clamped onto an existing solid conductor without having to disconnect the conductor.
Sign-up for Pulse Electronics’ Sidewinder Clamp-On Current Sensor Easily Fits Existing Solid Conductors investment picks
Pulse Electronics Corporation (NYSE: PULS), a leading provider of electronic components, introduces its new gate drive transformers for high efficiency DC/DC converters.
Sign-up for Pulse Electronics’ SMD Gate Drive Transformers Have a High HIPOT of 2700VDC, High Power Density, and Excellent Coplanarity investment picks
COMPANY TAPS BORREGA CONSULTING TO AGGRESSIVELY PURSUE NATIONAL GROCERY AND CONVENIENCE STORE LISTINGS DENVER , Aug.
Sign-up for Pulse Establishes International Presence In Mexico As Part Of Its Long-Term Growth Strategy investment picks
NATURAL CABANA® LEMONADE NOW AVAILABLE AT ALL 265 SMASHBURGER LOCATIONS NATIONWIDE DENVER , Aug.
Sign-up for Pulse Partners With Smashburger And Enters Multi-Billion Dollar Food Service Business investment picks
2014/9/30
Pulse Seismic Signs a $10.3 Million 3D Seismic Data License Canada NewsWire TSX Symbol - PSD OTCQX - PLSDF CALGARY , Sept.
Sign-up for Pulse Seismic Signs a $10.3 Million 3D Seismic Data License investment picks
Acquisition Expands PulteGroup's Midwest Operations into Columbus, Louisville and Lexington ATLANTA , Aug.
Sign-up for PulteGroup Acquires Real Estate Assets Of Dominion Homes investment picks
ATLANTA , Sept.
Sign-up for PulteGroup Announces Quarterly Cash Dividend Of $0.05 Per Share investment picks
Former Coca-Cola Executive Manish Shrivastava to Lead Consumer Inspired Marketing Efforts ATLANTA , Sept.
Sign-up for PulteGroup Names New Chief Marketing Officer investment picks
ATLANTA , July 24, 2014 /PRNewswire/ -- Q2 Earnings of $0.11 Per Share, After Charges of $0.14 Per Share for Insurance Reserves and Office Relocation Costs Q2 Pretax Income of $68 Million After Charges of $88 Million ; Q2 2013 Pretax Income of $38 Million After Charges of $67 Million Home Sale Revenues Increased 2% to $1.2 Billion Average Selling Price for Homes Delivered in the Quarter Increased 12% to $328,000 Gross Margin of 23.6% Expanded by 480 Basis Points Over Prior Year Value of Net New Orders Increased 5% to $1.6 Billion Higher Absorptions Per Community Drove Signups of 4,778 Homes Backlog Value at Quarter End of $2.8 Billion , Up from $2.7 Billion in 2013 7% Increase in Average Sales Price of Homes in Backlog to $339,000 Company Announces New $500 Million Senior Unsecured Revolving Credit Facility PulteGroup, Inc. (NYSE: PHM) announced
Sign-up for PulteGroup Reports Second Quarter 2014 Financial Results investment picks
Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced an amendment to its licensing agreement with Pfizer for Puma's investigational drug PB272 (neratinib). Puma is currently developing PB272 for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.
Sign-up for Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain.
Sign-up for Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014 investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that positive initial data from the ongoing, open label Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) with HER2 mutations was presented today as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, taking place in Madrid, Spain.
Sign-up for Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced top line results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET Trial). The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer.
Sign-up for Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial) investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2014.
Sign-up for Puma Biotechnology Reports Second Quarter 2014 Financial Results investment picks
NEW YORK (MarketWatch) -- Shares of Puma Biotechnology (PBYI) more than tripled in after-hours trade Tuesday after the company reported positive results from a late-stage trial of its breast cancer treatment.
Sign-up for Puma Biotechnology shares more than triple on postive trial data investment picks
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Puma Biotechnology, Inc. (NYSE:PBYI) in connection with possible claims of breaches of fiduciary duty by the Board of Directors.
Sign-up for PUMA BIOTECHNOLOGY, INC. SHAREHOLDER ALERT – Puma Biotechnology, Inc.: The Law Offices of Vincent Wong Launch an Investigation into Puma Biotechnology, Inc. investment picks
By Tomi Kilgore Puma Biotechnology shares' near quadrupling on heavy volume looks like an epic short squeeze, but relatively low levels of short interest suggests there may be more to the buying than just bears stampeding out of bad positions.
Sign-up for Puma's blast-off is not a typical short squeeze investment picks
2014/10/7
LONDON--Pub company Punch Taverns PLC (PUB.LN) Tuesday said Royal Bank of Scotland Group PLC (RBS.LN) has consented to its restructuring proposals.
Sign-up for Punch Taverns Receives Final Approval For Restructuring Proposals investment picks
Puradyn Filter Technologies Incorporated ( OTCQB: PFTI ), the global bypass oil filtration system manufacturer, today reported unaudited results of operations for the second fiscal quarter ended June 30, 2014.
Sign-up for Puradyn Releases 2014 2nd Quarter Unaudited Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Pulaski Financial Declares Quarterly Cash Dividend to Puradyn Releases 2014 2nd Quarter Unaudited Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices